The conversation discusses hair loss treatments, including finasteride, microneedling, minoxidil, and PTD-DBM. The user has not noticed significant regrowth and is considering cost-effective options like valproic acid.
The conversation discusses the lack of updates on GT20029 for hair loss treatment, with some users noting recent reports indicating ongoing data collection. There are mentions of other treatments like Pyrilutamide and Minoxidil.
The conversation is about a user's comprehensive hair loss treatment plan, including finasteride, minoxidil, dermaroller, Nizoral shampoo, vitamin D, biotin, and zinc. The user describes their approach as a strategic battle against DHT, with finasteride as the main treatment.
CRISPR shows promise for treating hair loss by targeting specific genes. Current treatments include Minoxidil and finasteride, but CRISPR could offer a more precise solution, though it is still expensive and in early stages.
Hair/scalp cloning for unlimited transplants is likely a decade away, with prior transplants not significantly affecting future options. Advances in AI and research in wound-induced hair neogenesis are promising, but infrastructure and technology constraints remain challenges.
The conversation discusses an extensive hair loss treatment regimen including dutasteride, GT20029, RU58841, pyrilutamide, minoxidil, microneedling, ketoconazole shampoo, and experimental compounds. The user humorously describes their approach as a comprehensive strategy to combat hair loss while maintaining hair growth.
The conversation is about the progress and development of a hair loss treatment called GT20029. People are discussing updates on its status and speculating on how long it will take to become available.
The conversation discusses the variability in effectiveness of medications, including finasteride, and questions whether different manufacturers impact results. The user suggests sharing successful brands to help others identify effective options.
Hair cloning was predicted to be a baldness cure within 3-4 years in 2004, but it has not materialized. Users express frustration and skepticism about the delay.
Hair multiplication or cloning is not available anywhere in the world. The conversation also mentions treatments like Minoxidil, finasteride, and RU58841 for hair loss.
The conversation discusses potential new treatments for androgenetic alopecia (AGA), including verteporfin, pyrilutamide, and hair cloning. There is optimism about scientific advancements providing alternatives to minoxidil and finasteride.
Amplifica's progress on Scube3 is unclear, with no recent updates. The conversation also mentions Minoxidil, finasteride, and RU58841 as hair loss treatments.
Scientists have successfully grown functional hair follicles in the lab, marking a significant advancement in hair regeneration research. A user shared their personal experience with hair loss treatments, including Minoxidil and Finasteride, and plans to share a detailed protocol for hair restoration.
PP405 is a potential hair loss treatment that may work by blocking signals that cause hair cells to stop growing, requiring daily application for effectiveness. It could serve as an alternative to minoxidil and finasteride, but it is not yet available on the market and may take several years to be released.
The conversation discusses HMI 115, a new hair loss treatment with promising results, showing a significant increase in hair density after two months. Some users are skeptical, while others are hopeful for its release and potential affordability.
GT20029 shows promising results for hair loss treatment, with potential approval in China by 2026 or 2027, but U.S. approval may take longer. It could serve as an alternative to finasteride, with a potentially better side effect profile.
A permanent hair loss solution could involve reprogramming hair follicles to resist DHT using mRNA and siRNA. However, high costs, safety concerns, and the pharmaceutical industry's preference for ongoing treatments over one-time cures are major obstacles, with finasteride and minoxidil remaining standard treatments.
The conversation is about the effectiveness of hair loss treatments, specifically finasteride and dutasteride, in different populations. Some users believe that the results of Japanese studies may not be relevant to Caucasian men, especially young ones, and that East Asians may respond better to these treatments. Others argue that clinical studies should be the basis for decision-making, while acknowledging that individual responses to medications can vary.
Bruce Willis's past comments on hair restoration and the progress of hair loss treatments like Minoxidil, Finasteride, and transplants. Users discuss the challenges of hair loss, the limited number of bald celebrities who are seen as role models, and the ongoing hope for future treatments.
PP405 is discussed as a potential hair loss treatment, with doubts about its effectiveness and availability. Users mention using finasteride and minoxidil, and express concerns about PP405's cost and market release.
PP405 is considered a promising hair loss treatment, potentially replacing minoxidil but not finasteride. Users are hopeful for future treatments like GT20029 and VDPHL01, while remaining cautious about effectiveness and side effects.
The conversation is about the potential cost of GT20029 if FDA approved, with estimates around $150/month. Comparisons are made between GT20029, finasteride, and their mechanisms and side effects.
Developing new hair loss treatments is challenging due to the complexity and cost of trials, and a permanent cure is unlikely soon. Current treatments like Minoxidil and finasteride are used continuously because hair loss is progressive, and future possibilities include gene editing and hair cloning.
People are eagerly awaiting the release of PP405, a new hair loss treatment. Some are using minoxidil and finasteride in the meantime, but there are concerns about scams and unverified products.
PP405 might make minoxidil unnecessary, but finasteride or other 5AR inhibitors may still be needed. PP405 is expected to be expensive and not available until at least 2028, with limited information on its effectiveness.
Hair cloning is discussed, focusing on its current status and potential availability. Treatments mentioned include Minoxidil, finasteride, and RU58841.
The conversation discusses purchasing experimental hair loss treatments KX-826, AHK-Cu, and PTD-DBM, with the user already using Minoxidil and having side effects from Finasteride. Concerns about the legitimacy of certain suppliers and the authenticity of products like pp405 are also mentioned.
PP405 is a medicine, and Google Ventures is funding its development based on evidence from each phase, unlike their investment in Juicero, which was a trend-based gamble. Investing in medicine is a calculated risk, not reliant on being "cool."